GBM cell lines and VEGF treated hBMVEC showed significantly higher Akt/mTOR activity (Figure 1A) versus the negative control (hBMVEC without VEGF) and cutoff of ELISA determinations. This evidence concerns the gene VEGFA and glioblastoma.